425: Bellevue Life Sciences Acquisition Corp. Secures $20 Million PIPE Investment from Toonon Partners

Bellevue Life Sciences Acquisition Corp. has entered into a subscription agreement with Toonon Partners Co., Ltd. for a $20 million PIPE investment to support its business combination with OSR Holdings Co., Ltd.

Summary

• Bellevue Life Sciences Acquisition Corp. (BLAC) has entered into a subscription agreement with Toonon Partners Co., Ltd. on October 4, 2024.
• Toonon will purchase 222,222 shares of Series A Preferred Stock of BLAC for $20 million, at a price of $90.00 per share.
• The Series A Preferred Stock will have a dividend accrual rate of 5% per annum, payable when declared by the board.
• Toonon can convert the Series A Preferred Stock into common stock at an initial conversion price of $9.00.
• BLAC has the option to redeem the Series A Preferred Stock beginning one year after the original issue date at a redemption price that includes accrued dividends at a rate of 7.0% per annum.
• Toonon can demand redemption beginning three years after the original issue date at the same redemption price.
• The purpose of the PIPE investment is to raise additional capital for BLAC following its business combination with OSR Holdings Co., Ltd.
• BLAC will file a registration statement to register the common stock issuable upon conversion of the PIPE Shares.
• The PIPE Shares will be exempt from registration pursuant to Regulation S under the U.S. Securities Act of 1933.

Sentiment

Score: 7

Explanation: The announcement of a $20 million PIPE investment is generally positive, indicating investor confidence in the company's future prospects and providing additional capital for its business combination. However, the terms of the preferred stock and the contingencies involved temper the overall sentiment.

Positives

• The $20 million PIPE investment provides additional capital for BLAC following the business combination with OSR Holdings Co., Ltd.
• The subscription agreement includes customary representations, warranties, and conditions to closing, providing a level of security for both parties.
• The Series A Preferred Stock has a dividend accrual, offering a potential return to the investor.
• Toonon has the option to convert the preferred stock into common stock, allowing them to participate in the potential upside of the combined company.
• The agreement includes a registration rights agreement, ensuring Toonon can eventually sell the common stock received upon conversion.

Negatives

• The dividend on the Series A Preferred Stock is payable only when, as, and if declared by the board of directors, which introduces uncertainty for the investor.
• The redemption option for BLAC could limit Toonon's potential upside if exercised early.
• The conversion price is subject to adjustment, which could dilute Toonon's ownership stake.
• The closing of the PIPE investment is contingent on the consummation of the Business Combination, introducing risk if the merger is not completed.

Risks

• The closing of the PIPE Investment is contingent on the consummation of the Business Combination with OSR Holdings.
• The forward-looking statements in the report are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's ability to obtain or maintain the listing of the surviving company's common stock on Nasdaq is not guaranteed.
• The COVID-19 pandemic or other global health disruptions could impact the parties' ability to consummate the Business Combination and the business of OSR Holdings.
• The company may be unable to recognize the anticipated benefits of the proposed Business Combination.

Future Outlook

The company expects the PIPE investment to provide additional capital following the closing of its business combination with OSR Holdings Co., Ltd. The company will file a registration statement to register the common stock issuable upon conversion of the PIPE Shares.

Industry Context

PIPE (Private Investment in Public Equity) investments are a common way for SPACs (Special Purpose Acquisition Companies) like Bellevue Life Sciences Acquisition Corp. to raise capital to complete acquisitions. This investment signals confidence in the planned merger with OSR Holdings.

Comparison to Industry Standards

• The terms of the Series A Preferred Stock, including the dividend rate and redemption options, are fairly standard for PIPE investments in SPAC transactions.
• The initial conversion price of $9.00 is typical, often set slightly below the SPAC's initial share price to incentivize investment.
• Comparable companies that have used PIPE investments to fund acquisitions include Digital World Acquisition Corp. (DWAC) and Gores Metropoulos, Inc. (GMII).
• DWAC secured a $1 billion PIPE investment for its merger with Trump Media & Technology Group (TMTG).
• GMII raised $425 million in a PIPE to support its acquisition of United Wholesale Mortgage (UWMC).

Stakeholder Impact

• Shareholders may benefit from the additional capital raised through the PIPE investment.
• Employees of both Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd. may be impacted by the business combination.
• Customers of OSR Holdings Co., Ltd. may see changes in products or services as a result of the merger.
• Suppliers and creditors of both companies may be affected by the combined entity's operations.

Next Steps

• Bellevue Life Sciences Acquisition Corp. intends to file a Certificate of Designations with the Secretary of State of the State of Delaware.
• The Company and Toonon will enter into a registration rights agreement prior to Closing.
• The Company will file a registration statement to register the Common Stock issuable upon conversion of the PIPE Shares.
• The Company will seek stockholder approval for the proposed Business Combination.

Key Dates